CA3039510A1 - Immunogenic arginase peptides - Google Patents
Immunogenic arginase peptides Download PDFInfo
- Publication number
- CA3039510A1 CA3039510A1 CA3039510A CA3039510A CA3039510A1 CA 3039510 A1 CA3039510 A1 CA 3039510A1 CA 3039510 A CA3039510 A CA 3039510A CA 3039510 A CA3039510 A CA 3039510A CA 3039510 A1 CA3039510 A1 CA 3039510A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- arginase
- peptide
- arg
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16192794.2 | 2016-10-07 | ||
| EP16192794 | 2016-10-07 | ||
| PCT/EP2017/075443 WO2018065563A1 (en) | 2016-10-07 | 2017-10-06 | Immunogenic arginase peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3039510A1 true CA3039510A1 (en) | 2018-04-12 |
Family
ID=57123856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3039510A Pending CA3039510A1 (en) | 2016-10-07 | 2017-10-06 | Immunogenic arginase peptides |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10858642B2 (https=) |
| EP (2) | EP4406613A3 (https=) |
| JP (1) | JP7211938B2 (https=) |
| KR (1) | KR102674521B1 (https=) |
| CN (1) | CN109890399A (https=) |
| AU (1) | AU2017341112B2 (https=) |
| CA (1) | CA3039510A1 (https=) |
| DK (1) | DK3522905T3 (https=) |
| ES (1) | ES2992031T3 (https=) |
| FI (1) | FI3522905T3 (https=) |
| HR (1) | HRP20241486T1 (https=) |
| HU (1) | HUE069077T2 (https=) |
| IL (1) | IL265805B2 (https=) |
| LT (1) | LT3522905T (https=) |
| MX (1) | MX2019003970A (https=) |
| PL (1) | PL3522905T3 (https=) |
| PT (1) | PT3522905T (https=) |
| SI (1) | SI3522905T1 (https=) |
| WO (1) | WO2018065563A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017341112B2 (en) * | 2016-10-07 | 2024-06-27 | Io Biotech Aps | Immunogenic arginase peptides |
| GB201815549D0 (en) * | 2018-09-24 | 2018-11-07 | Io Biotech Aps | Arginase1 polypeptides |
| GB201818576D0 (en) * | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
| GB201912030D0 (en) * | 2019-08-21 | 2019-10-02 | Cancer Research Tech Ltd | Binding molecules |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| KR20240159833A (ko) | 2022-02-24 | 2024-11-06 | 아이오 바이오테크 에이피에스 | 아르기나아제 2 백신 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| US20110111424A1 (en) | 2001-06-21 | 2011-05-12 | Cell Signaling Technology, Inc. | Analysis of ubiquitinated polypeptides |
| WO2003038444A2 (en) | 2001-10-31 | 2003-05-08 | Pfizer Products Inc. | Biomarkers of liver function |
| CA2836155A1 (en) * | 2004-10-29 | 2006-05-11 | Board Of Trustees Of Michigan State University | Protection against herbivores |
| CA2742497C (en) | 2008-10-31 | 2024-01-23 | George Georgiou | Compositions of engineered human arginases and methods for treating cancer |
| WO2011008495A2 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| CN106456723B (zh) | 2014-04-29 | 2021-03-09 | 康达医药科技有限公司 | 采用精氨酸酶i调节免疫系统的方法和组合物 |
| GB201501017D0 (en) * | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| AU2017341112B2 (en) * | 2016-10-07 | 2024-06-27 | Io Biotech Aps | Immunogenic arginase peptides |
| JP7312106B2 (ja) * | 2016-10-27 | 2023-07-20 | アイオー バイオテック エーピーエス | 新しいｐｄｌ２化合物 |
-
2017
- 2017-10-06 AU AU2017341112A patent/AU2017341112B2/en active Active
- 2017-10-06 SI SI201731553T patent/SI3522905T1/sl unknown
- 2017-10-06 HU HUE17786870A patent/HUE069077T2/hu unknown
- 2017-10-06 JP JP2019518424A patent/JP7211938B2/ja active Active
- 2017-10-06 HR HRP20241486TT patent/HRP20241486T1/hr unknown
- 2017-10-06 EP EP24166247.7A patent/EP4406613A3/en active Pending
- 2017-10-06 US US16/339,606 patent/US10858642B2/en active Active
- 2017-10-06 DK DK17786870.0T patent/DK3522905T3/da active
- 2017-10-06 LT LTEPPCT/EP2017/075443T patent/LT3522905T/lt unknown
- 2017-10-06 ES ES17786870T patent/ES2992031T3/es active Active
- 2017-10-06 FI FIEP17786870.0T patent/FI3522905T3/fi active
- 2017-10-06 IL IL265805A patent/IL265805B2/en unknown
- 2017-10-06 CA CA3039510A patent/CA3039510A1/en active Pending
- 2017-10-06 KR KR1020197012953A patent/KR102674521B1/ko active Active
- 2017-10-06 PT PT177868700T patent/PT3522905T/pt unknown
- 2017-10-06 WO PCT/EP2017/075443 patent/WO2018065563A1/en not_active Ceased
- 2017-10-06 EP EP17786870.0A patent/EP3522905B1/en active Active
- 2017-10-06 MX MX2019003970A patent/MX2019003970A/es unknown
- 2017-10-06 PL PL17786870.0T patent/PL3522905T3/pl unknown
- 2017-10-06 CN CN201780066414.6A patent/CN109890399A/zh active Pending
-
2020
- 2020-10-21 US US17/076,680 patent/US11981944B2/en active Active
-
2023
- 2023-10-26 US US18/495,466 patent/US20240167013A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019003970A (es) | 2019-12-05 |
| KR20190077381A (ko) | 2019-07-03 |
| IL265805B1 (en) | 2024-04-01 |
| PT3522905T (pt) | 2024-10-02 |
| AU2017341112A1 (en) | 2019-05-02 |
| IL265805A (en) | 2019-06-30 |
| DK3522905T3 (da) | 2024-10-21 |
| JP2019537562A (ja) | 2019-12-26 |
| WO2018065563A1 (en) | 2018-04-12 |
| IL265805B2 (en) | 2024-08-01 |
| KR102674521B1 (ko) | 2024-06-11 |
| CN109890399A (zh) | 2019-06-14 |
| EP3522905A1 (en) | 2019-08-14 |
| US10858642B2 (en) | 2020-12-08 |
| EP4406613A2 (en) | 2024-07-31 |
| SI3522905T1 (sl) | 2025-02-28 |
| HUE069077T2 (hu) | 2025-02-28 |
| LT3522905T (lt) | 2024-11-11 |
| FI3522905T3 (fi) | 2024-10-31 |
| EP3522905B1 (en) | 2024-09-25 |
| ES2992031T3 (es) | 2024-12-05 |
| EP4406613A3 (en) | 2024-10-23 |
| HRP20241486T1 (hr) | 2025-01-03 |
| US11981944B2 (en) | 2024-05-14 |
| US20190338270A1 (en) | 2019-11-07 |
| US20240167013A1 (en) | 2024-05-23 |
| PL3522905T3 (pl) | 2025-01-07 |
| JP7211938B2 (ja) | 2023-01-24 |
| AU2017341112B2 (en) | 2024-06-27 |
| US20210139877A1 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240167013A1 (en) | Immunogenic arginase peptides | |
| RU2721574C2 (ru) | Вакцинная композиция против злокачественной опухоли | |
| EP3112378B1 (en) | Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide | |
| US20090068209A1 (en) | Cytotoxic Lymphocyte | |
| US20250236658A1 (en) | Pdl2 compounds | |
| ES2510493T3 (es) | Epítopos T CD4+ de la Survivina y sus aplicaciones | |
| HK40012895B (en) | Immunogenic arginase peptides | |
| HK40012895A (en) | Immunogenic arginase peptides | |
| WO2019038235A1 (en) | NOVEL CCL2 PEPTIDES FOR USE IN ANTICANCER THERAPY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20201207 |
|
| FZDC | Discontinued application reinstated |
Effective date: 20211217 |
|
| FZDC | Discontinued application reinstated |
Effective date: 20211217 |
|
| EEER | Examination request |
Effective date: 20220829 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250801 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250801 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20251113 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260224 |